Thu, Nov 27, 2014, 5:57 AM EST - U.S. Markets closed for Thanksgiving Day


% | $
Quotes you view appear here for quick access.

Biogen Idec Inc. Message Board

  • berblady berblady May 24, 1998 6:24 PM Flag


    While wandering around the internet this
    afternoon, I came across a biotech "rumor mill" available
    through the Westergaard web site. One of the "rumors"
    posted by "anonymous" (most of these postings are by
    that same, widely read author) is as

    "Re Coulter Biotech. The I131 has an (approximate) 8
    day half life and labeling can be done at a central
    location and the product can be shipped to centers. The
    Rituxan has to be labeled at the centers. If efficacy is
    the same Bexxar may have an edge due to convenience
    of use."

    Does anyone know if this is so? And
    if it is, does it really make any difference if the
    radiolabeling is done prior to shipment or at the site? Either
    way, the treatment has to be administered in a nuclear
    medicine setting, doesn't it? Or is it possible that if
    the radiolabeling is done before shipment, shipment
    could be directly to oncologists' offices?

    time ago, some one posted that he had heard that IDEC
    was having difficulty getting the yttrium to stick to
    the monoclonal antibody. Some time after that, I read
    an IDEC press release in which they said they were
    able to get the yttrium to stick without any trouble
    (never having said earlier, one way or the other, that
    they had encountered any problems.)

    comments? (I'm posting this same "information on the
    Coulter thread.)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It is my understanding that site labeling will be
      more expensive than central labeling. This is not the
      most significant difference between the labeled Idec
      product and Bexxar. The problem with Y as a label is that
      you cannot give as precise of a dose as with I since
      Y has no gamma emissions. Idec will need to doce to
      body weight unlike Coulter which doses to clearance
      rate. The Idec product will probably beat up the bone
      marrow in more patients.

      • 2 Replies to geneT51
      • Thanks, geneT51 and oexwiz, for your

        Oexwiz: did Coulter announce they were working with Y-90
        labeled antibody? Where/when? I seem to have missed

        GeneT51: please bear with me. I don't know much about the
        technology of this stuff. Why would Idec's treatment beat up
        bone marrow more than Coulter's? One Sloan Kettering
        oncologist told me he/she thought yttrium treatment would be
        "better" because yttrium is not radioactive. In one of
        Coulter's recent press releases, they added to the usual
        statement about flu-like side effects, that some patients
        had required transfusions. Seems they're beginning to
        admit more side effects than previously.

      • If I-131 has so much going for it, why did Coulter announce doing trials with their own Y-90 labeled antibody?

304.92-0.48(-0.16%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.